Skip to main content
    I

    Innoviva Inc (INVA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.49
    -0.54 (-2.84%)

    Market Cap: $1.35B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Innoviva Inc (INVA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Innoviva reported revenue of $411.33M for the fiscal year ended Dec 31, 2025, up 14.7% from the year before. That year, net income was $271.17M with a net margin of 65.9%, operating cash flow was $196.93M and free cash flow was $195.80M. The quarter ended Sep 30, 2026 had revenue of $106.12M and net income of -$73.89M.

    Revenue and Margins

    The operating margin was 39.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $133.57M, a compound annual rate of 13.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$411.33M+14.7%74.8%39.8%65.9%
    Dec 2024$358.71M+15.5%82.6%46.5%6.5%
    Dec 2023$310.46M-6.3%79.2%36.7%57.9%
    Dec 2022$331.34M-15.4%95.8%96.7%66.5%
    Dec 2021$391.87M+16.4%100.0%119.0%94.1%
    Dec 2020$336.79M+29.0%100.0%110.3%87.2%
    Dec 2019$261.02M0.0%100.0%94.4%73.2%
    Dec 2018$261.00M+20.2%100.0%91.3%155.7%
    Dec 2017$217.22M+62.6%100.0%84.5%61.8%
    Dec 2016$133.57MN/A100.0%81.6%89.1%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 1059.3% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$411.33M$358.71M$310.46M$331.34M$391.87M$336.79M$261.02M$261.00M$217.22M$133.57M
    Cost of revenue$103.66M$62.50M$64.42M$13.79M$0$0$0$0$0$0
    Gross profit$307.67M$296.21M$246.04M$317.55M$391.87M$336.79M$261.02M$261.00M$217.22M$133.57M
    Research and development$30.60M$13.65M$33.92M$41.43M$576.00K$1.79M$0$0$1.35M$1.39M
    Operating income$163.75M$166.87M$113.89M$320.40M$466.13M$371.40M$246.36M$238.25M$183.60M$108.99M
    Net income$271.17M$23.39M$179.72M$220.26M$368.84M$293.81M$190.99M$406.33M$134.27M$119.07M
    EBITDA$223.16MN/A$157.81M$338.60M$485.48M$392.81M$265.13M$253.59M$195.23M$128.07M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$106.12M$119.59M$97.99M$114.61M$107.80M$100.28M$88.63M$91.81M$89.51M$99.90M$77.50M$85.84M
    Gross profit$84.38M$90.62M$75.83M$75.67M$75.54M$83.15M$73.31M$78.13M$73.01M$84.99M$60.09M$50.93M
    Operating income$42.15M$50.85M$38.15M$38.99M$34.58M$48.75M$41.43M$43.14M$43.24M$54.69M$25.80M-$25.47M
    Net income-$73.89M-$83.42M$186.59M$164.15M$89.91M$63.69M-$46.58M$20.33M$1.21M-$34.69M$36.53M$61.53M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $258.15M by $292.79M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.64B$1.30B$1.24B$1.23B$926.39M$999.57M$724.83M$548.19M$367.34M$379.00M
    Current assets$727.51M$554.31M$344.22M$443.51M$313.67M$342.06M$431.23M$199.04M$200.37M$198.05M
    Cash and equivalents$550.94M$304.96M$193.51M$291.05M$201.53M$246.49M$278.10M$62.42M$73.34M$118.02M
    Total liabilities$462.32M$609.90M$568.55M$665.71M$400.46M$391.73M$382.71M$389.14M$610.04M$731.99M
    Short-term debt$418.00K$192.03M$0$96.19M$0$25.00MN/AN/A$25.00M$7.75M
    Long-term debt$257.73M$256.32M$446.23M$444.18M$394.65M$385.52M$377.12M$382.86M$574.36M$708.34M
    Shareholder equity$1.17B$691.16M$674.96M$565.79M$414.74M$539.91M$313.50M$153.58M-$242.86M-$352.99M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.54B$1.70B$1.84B$1.64B$1.43B$1.33B$1.25B$1.30B$1.23B$1.22B$1.27B$1.24B
    Total liabilities$400.41M$469.46M$494.93M$462.32M$419.15M$618.75M$607.49M$609.90M$563.07M$559.40M$563.93M$568.55M
    Cash and equivalents$581.39M$570.39M$603.09M$550.94M$476.51M$397.53M$319.09M$304.96M$260.63M$217.00M$178.36M$193.51M
    Shareholder equity$1.14B$1.23B$1.34B$1.17B$1.01B$714.82M$646.90M$691.16M$668.54M$665.51M$703.68M$674.96M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 99.4% of operating cash flow. Share repurchases came to 2.3% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$196.93M$188.69M$141.06M$201.73M$363.81M$313.11M$257.46M$223.53M$141.75M$60.98M
    Capital expenditures$1.13M$270.00K$411.00K$67.00K$0$13.00K$12.00K$0$0$278.00K
    Free cash flow$195.80M$188.42M$140.65M$201.66M$363.81M$313.10M$257.45M$223.53M$141.75M$60.71M
    Dividends paidN/AN/A$96.28M$69.81M$59.46M$30.47M$10.56M$6.04M$258.00K$960.00K
    Share repurchases$4.53M$14.78M$75.73M$8.50M$394.15M$0$0N/A$97.50M$78.09M
    Investing cash flow$40.50M-$63.79M-$66.76M-$56.63M$43.72M-$314.94M-$18.00M$3.52M-$23.24M-$4.58M
    Financing cash flow$8.55M-$13.45M-$171.84M-$55.57M-$452.50M-$29.79M-$23.78M-$237.97M-$163.19M-$97.57M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$41.70M$51.97M$35.28M$54.51M$49.73M$44.07M$48.62M$59.24M$48.69M$43.72M$37.05M$33.26M
    Capital expenditures$24.00K$429.00K$492.00K$10.00K$1.12M$0$0$4.00M$270.00K$0$0$151.00K
    Free cash flow$41.67M$51.54M$34.79M$54.50M$48.61M$44.07M$48.62M$55.24M$48.42M$43.72M$37.05M$33.10M
    Last 12 quarters

    Frequently Asked Questions About INVA

    What is Innoviva's annual revenue?

    Innoviva reported revenue of $411.33M for the fiscal year ended Dec 31, 2025.

    How fast is Innoviva's revenue growing?

    Revenue was up 14.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 7.5%.

    Is Innoviva profitable?

    Yes. Innoviva reported net income of $271.17M for the fiscal year ended Dec 31, 2025, with a net margin of 65.9%.

    How much free cash flow does INVA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $196.93M minus capital expenditures of $1.13M produced free cash flow of $195.80M.

    How much debt does Innoviva have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $257.73M, short-term debt of $418.00K and cash and equivalents of $550.94M.